natgillin/translations-raw huggingface dataset:
Figur 2 Kaplan-Meier kurve over progressionsfri overlevelse udfra uafhængig vurdering i undergruppen med tidligere sunitinib-behandling. 
Kaplan-Meier curve of progression-free survival by independent assessment for the prior sunitinib subgroup
Virkning og anvendelse Det skal du vide, før du begynder at tage Inlyta Sådan skal du tage Inlyta Bivirkninger 
What Inlyta is and what it is used for What you need to know before you take Inlyta How to take Inlyta
Axitinib er ikke undersøgt hos patienter, som har haft venøse tromboemboliske hændelser inden for de sidste 6 måneder. 
Axitinib has not been studied in patients who had a venous embolic or thrombotic event within the previous 6 months.
• Ændringer i stoffer/enzymer i blodet. 
• Changes in the levels of different chemicals/enzymes in the blood (may show in your blood tests)
• Hvis du for nylig har haft problemer med blodpropper, inklusive slagtilfælde og hjertetilfælde. 
• If you have had a recent problem with blood clots in your veins and arteries (types of blood vessels), including stroke, heart attack, embolism, or thrombosis.
HDPE beholder med silicagel tørrekapsel og polypropylenlåg indeholdende 60 filmovertrukne tabletter. 
HDPE bottle with a silica gel desiccant and a polypropylene closure containing 60 film-coated tablets.
Bivirkninger set i RCC-studier hos patienter behandlet med axitinib (N = 672) Systemorganklasse Hyppighed 
Adverse reactions reported in RCC studies in patients who received axitinib (N = 672)
Sådan skal du tage Inlyta 
How to take Inlyta
• Røde blodlegemer i urinen (ses i urinprøver) 
• Presence of red blood cells in the urine (may show in your urine tests)
In vitro data antyder, at axitinib primært metaboliseres via CYP3A4/5 og i mindre udstrækning via CYP1A2, CYP2C19 og uridindiphosphat-glucuronosyltranferase (UGT) 1A1. 
In vitro data indicate that axitinib is metabolised primarily by CYP3A4/5 and, to a lesser extent, CYP1A2, CYP2C19, and uridine diphosphate-glucuronosyltransferase (UGT) 1A1.
Alle grader 
All Gradesb
Dosisreduktion anbefales til patienter med moderat nedsat leverfunktion (Child-Pugh klasse B) (se pkt. 
A dose decrease is recommended when administering axitinib to patients with moderate hepatic impairment (Child-Pugh class B) (see section 4.2).
Selvom dosisjustering af axitinib ikke er undersøgt hos patienter i behandling med potente CYP3A4/5hæmmere, anbefales det at reducere axitinib-dosis til ca. halvdelen (f.eks bør startdosis nedsættes fra 5 mg 2 gange dagligt til 2 mg 2 gange dagligt), hvis axitinib skal administreres sammen med en kraftig CYP/3A4/5-hæmmer. 
Although axitinib dose adjustment has not been studied in patients receiving strong CYP3A4/5 inhibitors, if a strong CYP3A4/5 inhibitor must be co-administered, a dose decrease of axitinib to approximately half the dose (e.g. the starting dose should be reduced from 5 mg twice daily to 2 mg twice daily) is recommended.
Vurderet ved uafhængig radiologisk gennemgang i henhold til Response Evaluation Criteria in Solid Tumours (RECIST). 
Cutoff date: 03 June 2011. b Assessed by independent radiology review according to Response Evaluation Criteria in Solid
• Fistel-dannelse (unormal rør-lignende passage fra et hulrum i kroppen til et andet eller til huden) 
• Fistula (abnormal tube like passage from one normal body cavity to another body cavity or the skin)
Hjertesvigt c, d, f 
Cardiac failure eventsc,d,f
I et klinisk studie med axitinib til behandling af patienter med RCC, så man hypotyreose hos 20,9% af patienterne og hypertyreose hos 1,1% af patienterne. 
In a controlled clinical study with axitinib for the treatment of patients with RCC, hypothyroidism was reported in 20.9% of patients and hyperthyroidism was reported in 1.1% of patients.
I et kontrolleret klinisk studie med axitinib til behandling af patienter med RCC var 34% af patienterne over 65 år gamle. 
In a controlled clinical study with axitinib for the treatment of patients with RCC, 34% of patients treated with axitinib were ≥ 65 years of age.
Ring straks til lægen, hvis du får symptomer såsom hovedpine, forvirring, kramper og synsforstyrrelser, med eller uden for højt blodtryk. 
Get emergency help right away and call your doctor if you get symptoms such as headache, confusion, seizures (fits), or changes in vision with or without high blood pressure.
Inlyta 1 mg filmovertrukne tabletter Inlyta 3 mg filmovertrukne tabletter Inlyta 5 mg filmovertrukne tabletter Inlyta 7 mg filmovertrukne tabletter 
Inlyta 1 mg film-coated tablets Inlyta 3 mg film-coated tablets Inlyta 5 mg film-coated tablets Inlyta 7 mg film-coated tablets
Arterielle tromboemboliske hændelser c, d, j 
Arterial embolic and thrombotic eventsc,d,j
Bivirkninger, hvor hyppigheden ikke er kendt 
Not known: frequency cannot be estimated from the available data
Der skal monitoreres for symptomer på gastrointestinal perforation og fistler under hele behandlingen med axitinib. 
Symptoms of gastrointestinal perforation or fistula should be periodically monitored for throughout treatment with axitinib.
Nedsat nyrefunktion Uomdannet axitinib genfindes ikke i urin. 
Unchanged axitinib is not detected in the urine.
Inlyta indeholder: 
What Inlyta contains
Effekt Endepunkt/ studiepopulation axitinib sorafenib 
Efficacy results Endpoint / study population axitinib sorafenib HR (95% CI) p-value
Håndteringen af nogle af bivirkningerne kan kræve midlertidig eller permanent afbrydelse af behandlingen og/eller dosisnedsættelse af axitinib (se pkt. 
Management of some adverse reactions may require temporary or permanent discontinuation and/or dose reduction of axitinib therapy (see section 4.4).
Det er nødvendigt at MR-skanne patienten for at stille PRES-diagnosen. 
Magnetic resonance imaging is necessary to confirm the diagnosis of PRES.
Skema 1. 
Figure 1.
Samtidig administration af axitinib og potente CYP3A4/5-induktorer (f.eks. rifampicin, dexamethason, phenytoin, carbamazepin, rifabutin, rifapentin, phenobarbital og perikon) kan nedsætte plasmakoncentrationen af axitinib. 
Co-administration of axitinib with strong CYP3A4/5 inducers (e.g. rifampicin, dexamethasone, phenytoin, carbamazepine, rifabutin, rifapentin, phenobarbital, and Hypericum perforatum [St.
Spørg lægen, på apotekespersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om. 
You should check with your doctor, pharmacist or nurse if you are not sure.
Figur 3 Kaplan-Meier kurve over progressionsfri overlevelse udfra uafhængig vurdering i undergruppen med tidligere cytokin-behandling. 
Kaplan-Meier curve of progression-free survival by independent assessment for the prior cytokine subgroup
Dosisjustering er ikke nødvendig hos patienter med let nedsat leverfunktion (Child-Pugh klasse A). 
No dose adjustment is required when administering axitinib to patients with mild hepatic impairment (Child-Pugh class A).
Hvis behandlingen med axitinib afbrydes, bør blodtrykket kontrolleres med henblik på hypotension hos patienter i antihypertensiv behandling (se pkt. 
If axitinib is interrupted, patients receiving antihypertensive medicinal products should be monitored for hypotension (see section 4.2).
I kliniske studier med axitinib til behandling af patienter med RCC, blev hypertension meget hyppigt rapporteret (se pkt. 
In clinical studies with axitinib for the treatment of patients with RCC, hypertension was very commonly reported (see section 4.8).
In vitro studier antyder, at axitinib er en potentiel hæmmer af CYP2C8. 
In vitro studies also indicated that axitinib has the potential to inhibit CYP2C8.
Axitinib er en potent og selektiv hæmmer af VEGF (Vascular Endothelial Growth Factor). 
Axitinib is a potent and selective tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, VEGFR-2 and VEGFR-3.
• Fald i antal blodplader (der gør at blodet har sværere ved at størkne) (ses i blodprøver) 
• Reduction in the number of blood platelets (cells that help blood to clot) (may show in your blood tests)
Kontakt omgående læge eller skadestue, ved symptomer som smerter eller trykken for brystet, smerter i armene, ryggen, nakken eller kæben, åndenød, følelsesløshed eller svaghed i den ene side af kroppen, problemer med at tale, hovedpine, synsforstyrrelser eller svimmelhed, mens du bliver behandlet med dette lægemiddel. 
Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes; or dizziness while on treatment with this medicine.
DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN 
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 3 September 2012
Hvis skjoldbruskkirtlen ikke producerer nok hormon, kan der gives et medicinsk tilskud af skjoldbruskkirtelhormon. 
If your thyroid gland is not producing enough thyroid hormone before, or while on treatment with this medicine, you should be treated with thyroid hormone replacement.
Der sås ingen virkning på parringsevne og fertilitet hos hanmus ved doser ca. 57 gange human-terapeutiske doser. 
There was no effect on mating or fertility in male mice at exposure levels approximately 57-fold the expected human exposure.
Skjoldbruskkirtlens funktion skal måles, inden du begynder at tage Inlyta og regelmæssigt under behandlingen. 
Your thyroid function should be checked before you take Inlyta and regularly while you are taking it.
Fortæl det til lægen, hvis du oplever usædvanlig træthed, opsvulmet mave, hævede ben eller ankler, åndenød eller fremstående blodårer på halsen. 
Tell your doctor if you experience excessive tiredness, swelling of the abdomen, legs, or ankles, shortness of breath, or protruding neck veins.
In vitro studier antyder, at axitinib er en potentiel hæmmer af CYP1A2. 
In vitro studies indicated that axitinib has a potential to inhibit CYP1A2.
Inlyta 1 mg filmovertrukne tabletter Inlyta 3 mg filmovertrukne tabletter Inlyta 5 mg filmovertrukne tabletter Inlyta 7 mg filmovertrukne tabletter axitinib 
Inlyta 1 mg film-coated tablets Inlyta 3 mg film-coated tablets Inlyta 5 mg film-coated tablets Inlyta 7 mg film-coated tablets axitinib
I kliniske studier med axitinib til behandling af patienter med RCC blev der rapporteret hændelser med hjertesvigt (herunder hjertesvigt, kongestivt hjertesvigt, kardiopulmonalt svigt, venstre ventrikeldysfunktion, nedsat uddrivningsfraktion og højre ventrikelsvigt) (se pkt. 
In clinical studies with axitinib for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported (see section
Inlyta indeholder lactose 
Inlyta contains lactose (milk sugar)
Venøse tromboemboliske hændelser c, d, i 
Venous embolic and thrombotic eventsc,d,i
Stigning i lipase Stigning i alaninaminotransferase Stigning i amylase Stigning i aspartataminotransferase Stigning i basisk fosfatase Stigning i kreatinin Stigning i TSH 
Amylase increased Aspartate aminotransferase increased
I studier med axitinib givet som monoterapi (N = 672) til behandling af patienter med RCC blev der rapporteret hændelser med hjertesvigt (herunder hjertesvigt, kongestivt hjertesvigt, kardiopulmonalt svigt, venstre ventrikeldysfunktion, nedsat uddrivningsfraktion og højre ventrikelsvigt) hos 1,8 % af patienterne, der fik axitinib. 
In monotherapy studies with axitinib (N = 672) for the treatment of patients with RCC, cardiac failure events (including cardiac failure, cardiac failure congestive, cardiopulmonary failure, left ventricular dysfunction, ejection fraction decreased, and right ventricular failure) were reported in 1.8% patients receiving axitinib.
Det skal du vide, før du begynder at tage Inlyta 
What you need to know before you take Inlyta Do not take Inlyta:
Axitinib bør anvendes med forsigtighed hos patienter med risiko for eller som tidligere har haft en arteriel tromboembolisk hændelse. 
Axitinib should be used with caution in patients who are at risk for, or who have a history of, these events.
I kliniske studier med axitinib til behandling af patienter med RCC, blev der set tilfælde af hypotyreose, og i mindre udstrækning hypertyreose (se pkt. 
In clinical studies with axitinib for the treatment of patients with RCC, events of hypothyroidism and, to a lesser extent, hyperthyroidism, were reported (see section 4.8).
4.4 og 5.2). 
29.4 (24.5, NE)
Posteriort reversibelt encefalopati-syndrom (PRES) Der er set PRES i kliniske studier (se pkt. 
Posterior reversible encephalopathy syndrome (PRES) In clinical studies with axitinib, events of PRES were reported (see section 4.8).
Øvre abdominale smerter Flatulens 
Abdominal pain Constipation
Sikkerhed og virkning af dette lægemiddel til børn og unge er ikke klarlagt. 
This medicine has not been studied in children and adolescents.
• Fald i antal røde blodlegemer (ses i blodprøver) 
• Reduction in the number of red blood cells (may show in your blood tests)
Dødelig lungeemboli blev set hos 1 patient (0,3%) i behandling med axitinib. 
Fatal pulmonary embolism was reported in one patient (0.3%) receiving axitinib.
I et kontrolleret klinisk studie med axitinib som behandling af patienter med RCC er der set leverrelaterede bivirkninger. 
In a controlled clinical study with axitinib for the treatment of patients with RCC, liver-related adverse reactions were reported.
Men samtidig administration af axitinib forventes ikke at hæmme P-glykoprotein ved terapeutiske plasmakoncentrationer, og det forventes derfor ikke, at samtidig administration af axitinib vil medføre en stigning i plasmakoncentrationen af digoxin eller andre P-glykoproteinsubstrater in vivo. 
Therefore, co-administration of axitinib is not expected to increase the plasma concentration of digoxin, or other P-glycoprotein substrates,
Forlængelsen af den mediane progressionfri overlevelse var forskellig i de to undergrupper afhængigt af den tidligere behandling. 
The magnitude of median PFS effect was different in the subgroups by prior therapy.
Ring straks til lægen ved symptomer som smerter eller trykken for brystet, smerter i armene, ryggen, nakken eller kæben, åndenød, følelsesløshed eller svaghed i den ene side af kroppen, problemer med at gå, hovedpine, synsforstyrrelser eller svimmelhed. 
Get emergency help right away and call your doctor if you get symptoms such as chest pain or pressure; pain in your arms, back, neck or jaw; shortness of breath; numbness or weakness on one side of your body; trouble talking; headache; vision changes: or dizziness.
• Forhøjet antal røde blodlegemer (ses i blodprøver) 
• Increase in the number of red blood cells (may show in your blood tests)
Din læge vil jævnligt undersøge Dem for symptomer på hjertesvigt under behandlingen med axitinib. 
Your doctor should monitor for signs or symptoms of heart failure events periodically throughout treatment with axitinib.
4.4: hjertesvigt, hypertension, thyroideadysfunktion, arterielle tromboemboliske hændelser, venøse tromboemboliske hændelser, stigning i hæmoglobin eller hæmatokrit, blødning, gastrointestinal perforation og fisteldannelse, komplikationer ved sårheling, PRES, proteinuri og stigning i leverenzymer. 
The following risks, including appropriate action to be taken, are discussed in greater detail in section 4.4: cardiac failure events, hypertension, thyroid dysfunction, arterial thromboembolic events, venous thromboembolic events, elevation of haemoglobin or haematocrit, haemorrhage, gastrointestinal perforation and fistula formation, wound healing complications, PRES, proteinuria, and elevation of liver enzymes.
• Diarré, kvalme, opkastning, mavesmerter, fordøjelsesproblemer, øm mund, tunge og svælg, 
• Diarrhoea, feeling or being sick (nausea or vomiting), stomach ache, indigestion, soreness of the mouth, tongue or throat, constipation
• Næseblod 
• Nose bleeding
I studier med axitinib givet som monoterapi (N = 850) så man arterielle tromboemboliske bivirkninger (herunder transitoriske iskæmisk anfald, myokardieinfarkt og cerebrovaskulære hændelser) hos 5,3% af patienterne. 
In monotherapy studies with axitinib (N = 850), arterial embolic and thrombotic adverse reactions (including transient ischemic attack, myocardial infarction, and cerebrovascular accident) were reported in 5.3% of patients receiving axitinib.
Gastrointestinal perforation og fistler inkluderer følgende termer: abdominal absces, anal absces, anal fistel, fistel, gastrointestinal anastomose lækage, gastrointestinal perforation, tyktarmsperforation, øsofagobronkial fistel og peritonitis Proteinuri inkluderer følgende termer: protein i urinen, protein til stede i urinen og proteinuri Inklusive akut nyresvigt n Cholecystitis inkluderer akut cholecystitis, cholecystitis, infektiøs cholecystitis 
k Gastrointestinal perforation and fistula includes the following preferred terms: abdominal abscess, anal abscess, anal fistula, fistula, gastrointestinal anastomotic leak, gastrointestinal perforation, large intestine perforation, oesophagobronchial fistula and peritonitis.
Meget almindelig Hypertension Blødning c, d, h 
Vascular disorders Very common Hypertensiong Haemorrhagec,d,h
I et kontrolleret klinisk studie med axitinib (N = 359) til behandling af patienter med RCC blev der rapporteret tilfælde af hjertesvigt hos 1,7 % af patienterne, der fik axitinib, herunder hjertesvigt (0,6 %), kardiopulmonalt svigt (0,6%), venstre ventrikeldysfunktion (0,3 %) og højre ventrikelsvigt (0,3 %). 
In a controlled clinical study with axitinib (N = 359) for the treatment of patients with RCC, cardiac failure events were reported in 1.7 % patients receiving axitinib, including cardiac failure (0.6%), cardiopulmonary failure (0.6%), left ventricular dysfunction (0.3%), and right ventricular failure
IS 
i
Pfizer Ελλάς A.E. Τλ: +30 210 6785 800 
Τηλ: +30 210 6785 800
I et klinisk studie med axitinib til behandling af patienter med RCC, hvor patienter med ubehandlede hjernemetastaser var blevet ekskluderet, blev der rapporteret blødningsrelaterede bivirkninger hos 21,4% af patienterne i behandling med axitinib. 
In a controlled clinical study with axitinib for the treatment of patients with RCC that excluded patients with untreated brain metastasis, haemorrhagic adverse reactions were reported in 21.4% of patients receiving axitinib.
Axitinib er ikke undersøgt hos patienter med nedsat nyrefunktion. 
Axitinib has not been studied in subjects with renal impairment.
Ved mistanke om overdoseringer bør behandlingen ophøre og understøttende behandling iværksættes. 
In cases of suspected overdose, axitinib should be withheld and supportive care instituted.
180 tabletter 
PHARMACEUTICAL FORM AND CONTENTS 180 tablets
I fire kliniske studier med axitinib til behandling af patienter med RCC (N = 537) så man hæmoglobinniveauer over det normale hos 13,6% af patienterne i behandling med axitinib. 
In four clinical studies with axitinib for the treatment of patients with RCC (N = 537), elevated haemoglobin above ULN was observed in 13.6% receiving axitinib.
Arterielle tromboemboliske hændelser (se pkt. 
Arterial embolic and thrombotic events (see section 4.4)
Thyroideadysfunktion (se pkt. 
Thyroid dysfunction (see section 4.4)
Patienter med serumkreatinin >1,5 gange den øvre normal grænse eller beregnet kreatininclearance <60 ml/min blev ekskluderet fra de kliniske studier. 
In clinical studies with axitinib for the treatment of patients with RCC, patients with serum creatinine > 1.5 times the ULN or calculated creatinine clearance < 60 mL/min were excluded.
Inlyta 1 mg fås i beholdere med 180 tabletter og i blisterpakninger med 14 tabletter. 
Inlyta 1 mg is available in bottles of 180 tablets and blisters of 14 tablets.
Blødningsrelaterede bivirkninger grad ≥3 blev set hos 3,1% af patienterne i behandling med axitinib (herunder hjerneblødning, gastrisk blødning, nedre gastrointestinal blødning og hæmoptyse). 
Grade > 3 haemorrhagic adverse reactions were reported in 3.1% of patients receiving axitinib (including cerebral haemorrhage, gastric haemorrhage, lower gastrointestinal haemorrhage and haemoptysis).
Proteinuri Der er rapporteret proteinuri, herunder grad 3- og 4-proteinuri, i kliniske studier med axitinib (se pkt. 
In clinical studies with axitinib, proteinuria, including that of Grade 3 and 4 severity, was reported (see section 4.8).
4.4) I et klinisk studie med axitinib til behandling af patienter med RCC, blev der rapporteret arterielle tromboemboliske bivirkninger hos 4,7% af de patienter,der fik axitinib, herunder myokardieinfarkt (1,4%), transitorisk cerebral iskæmi (0,8%) og cerebrovaskulære hændelser (0,6%). 
In a controlled clinical study with axitinib for the treatment of patients with RCC, arterial embolic and thrombotic adverse reactions were reported in 4.7% of patients receiving axitinib, including myocardial infarction (1.4%), transient ischemic attack (0.8%) and cerebrovascular accident (0.6%).
Axitinib er ikke undersøgt hos patienter med svært nedsat leverfunktion (Child-Pugh klasse C) og bør ikke anvendes til denne gruppe patienter. 
Axitinib has not been studied in patients with severe hepatic impairment (Child-Pugh class C) and should not be used in this population.
• Opsvulmet mave, hævede ben eller ankler, fremstående blodårer på halsen, usædvanlig træthed, 
• Swelling of the abdomen, legs, or ankles, protruding neck veins, excessive tiredness,
Meget almindelig Artralgi Ekstremitetssmerter 
Very common Arthralgia Pain in extremity
Dødelig blødning sås hos 1 patient (0,3%) i behandling med axitinib (gastrisk blødning). 
Fatal haemorrhage was reported in one patient (0.3%) receiving axitinib (gastric haemorrhage).
• Hvis du får symptomer såsom usædvanlig træthed, opsvulmet mave, hævede ben eller ankler, åndenød eller fremstående blodårer på halsen under behandling med Inlyta. 
• If during treatment with this medicine, you get symptoms such as excessive tiredness, swelling of the abdomen, legs or ankles, shortness of breath, or protruding neck veins.
Inlyta kan give problemer med skjoldbruskkirtlen. 
Inlyta can cause thyroid gland problems.
HR (95% CI) 
Median OS d in months (95% CI)
Der er set venøse tromboemboliske hændelser (herunder lungeemboli, dyb venetrombose og retinal vene okklusion/trombose) i kliniske studier med axitinib (se pkt. 
In clinical studies with axitinib, venous embolic and thrombotic events (including pulmonary embolism, deep vein thrombosis, and retinal vein occlusion/thrombosis) were reported (see section 4.8).
Venøse tromboemboliske hændelser (se pkt. 
Venous embolic and thrombotic events (see section 4.4)
4.4) I et klinisk studie med axitinib til behandling af patienter med RCC, blev der rapporteret venøse tromboemboliske hændelser hos 3,9% af patienterne, herunder lungeemboli (2,2%), retinalveneokklusion (trombose) (0,6%) og dyb venetrombose (0,6%). 
In a controlled clinical study with axitinib for the treatment of patients with RCC, venous embolic and thrombotic adverse reactions were reported in 3.9% of patients receiving axitinib, including pulmonary embolism (2.2%), retinal vein occlusion/thrombosis (0.6%) and deep vein thrombosis (0.6%).
Hypertyreose 
Hyperthyroidismc
• Hjertesvigt. 
• Heart failure events.
Behandling med axitinib kan medføre stigning i hæmoglobin eller hæmatokrit, som tegn på en øget mængde røde blodlegemer (se pkt. 
Increases in haemoglobin or haematocrit, reflective of increases in red blood cell mass, may occur during treatment with axitinib (see section 4.8, polycythaemia).
Samtidig anvendelse af potente CYP3A4/5-induktorer Samtidig anvendelse af axitinib og potente CYP3A4/5-induktorer kan nedsætte plasmakoncentrationen af axitinib (se pkt. 
Co-administration of axitinib with strong CYP3A4/5 inducers may decrease axitinib plasma concentrations (see section 4.5).
Leverfunktionen skal kontrolleres før initiering af behandlingen og regelmæssigt under hele behandlingen med axitinib. 
Liver function tests should be monitored before initiation of, and periodically throughout, treatment with axitinib.